Clinical Grade hESC Lines
Canham M.A, Van Deusen A., Brison D.R., De Sousa P.A., Downie J., Devito L., Hewitt Z.A., Ilic D., Kimber S.J., Moore H.D., Murray H., Kunath T. Scientific Reports 2015
It is essential to know the genetic stability of the hESC lines before progressing to clinical trials. In this study they evaluated the molecular karyotype of 25 clinical-grade hESC lines by whole-genome single nucleotide polymorphism (SNP) array analysis. The hESC lines were all cultured on laminin-521.
Xeno-Free and Defines hESC derived RPE's
Plaza Reyes A., Petrus-Reurer S., Antonsson L., Stenfelt S., Bartuma H., Panula S., Mader T., Douagi I., André H., Hovatta O., Lanner F., Kvanta A.
Stem Cell Reports, 2016
Here the authors describe production of hESC-RPE cells in a xeno-free and defined manner and present evidence of functional integration of clinically compliant hESC-RPE in a large-eyed disease model. Human recombinant laminin-521 effectively supports differentiation of clinically compliant hESC-RPE that are effeiciently used in a minimally invasive surgical procedure for high-yield functional long-term hESC-RPE integration with photoreceptor preservation. These findings have important implications for ongoing and future clinical studies for the development of a safe and efficient cell replacement therapy for geographic atrophy.
You can also watch Dr Agnete Kirkeby's brilliant presentation of her development of Dopaminergic neurons from hPSC's using laminin as extracellular matrix here